Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 6—June 2021

Macrolide-Resistant Mycoplasma pneumoniae Infections in Children, Ohio, USA

Mariana M. Lanata1, Huanyu Wang, Kathy Everhart, Melisa Moore-Clingenpeel, Octavio Ramilo, and Amy LeberComments to Author 
Author affiliation: Nationwide Children’s Hospital, Columbus, Ohio, USA

Main Article

Table 8

Antimicrobial drug treatment for children infected with Mycoplasma pneumoniae, Ohio, USA, 2015–2019*

Characteristic MRMp, n = 12 MSMp, n = 332 p value
Patients with previous antimicrobial drug treatment, no. (%) 5 (42) 106 (32) 0.5339
Nonmacrolide 5 (42) 102 (31) 0.5262
3 (25)
7 (2.1)
Definitive treatment during medical encounter, no. (%)
Azithromycin 9 (75) 317 (95.5) 0.0197
Levofloxacin 3 (25) 15 (4.5) 0.0267

*Bold type indicates statistical significance. MRMp, macrolide-resistant Mycoplasma pneumoniae; MSMp, macrolide-sensitive Mycoplasma pneumoniae.

Main Article

1Current affiliation: Marshall University, Huntington, West Virginia, USA.

Page created: March 30, 2021
Page updated: May 18, 2021
Page reviewed: May 18, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.